Lotus leaf tea or defined lotus leaf infusion,
does it really help with Reduction of systolic blood pressure in adults with hypertension?
research showsJudgment is deferred. No eligible trial was identified that assigned adults with hypertension to drink single-ingredient lotus-leaf tea or a defined infusion and compared office or 24-hour systolic blood pressure. An extract beverage body-fat trial, in-vitro ACE inhibition, and animal blood-pressure studies of seed extract do not answer this question.
ads claimTraditional use, ACE inhibition, nuciferine mechanisms, or animal blood-pressure results from other parts cannot support claims of treating human hypertension or replacing medication.
Useful facts when choosing a product
- This verdict applies only to the displayed lotus part, formulation, route, population, claim, endpoint, and comparator.
- Leaf, plumule, whole seed, rhizome, node, tea, extract, food, juice, and combination products are not interchangeable.
- Caution. Eligible trials do not establish dose, long-term safety, pregnancy or lactation safety, liver or kidney safety, or interactions with antihypertensive or glucose-lowering medicines.
Chamgap Semantic Classification Code
Candidate index · review held
F.lotus-leaf-tea.oral-drink.systolic-blood-pressure.reduce.UNKFoods and beverages > Lotus-leaf tea > Oral drink > Hypertension systolic blood pressure > Reduction claim > Comparator unknown
The claim scope is defined, but no eligible controlled human trial fixes dose, duration, or the primary comparator contract, so permanent issuance is held. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | F · Food, ingredient, or beverage |
|---|---|
| Canonical ingredient or intervention | Lotus leaf tea |
| Source or part used | Nelumbo nucifera leaf; cultivar, origin, and harvest timing unverified |
| Formulation or processing | Tea or defined hot-water infusion; no eligible trial formulation verified |
| Route | Oral drink |
| Dose | Unverified (no eligible controlled trial) |
| Duration | Unverified (no eligible controlled trial) |
| Population | Adults with hypertension |
| Effect or condition | Lower systolic blood pressure |
| Primary endpoint | Unverified; intended endpoint is office or 24-hour systolic blood pressure |
| Comparator | Unverified (no eligible controlled trial) |
| Duplicate-detection key | Lotus leaf tea|Tea or defined hot-water infusion; no eligible trial formulation verified|Oral drink|Adults with hypertension|Lower systolic blood pressure|Unverified (no eligible controlled trial) |
What the research actually shows
PubMed and ClinicalTrials.gov were searched using combinations of Nelumbo, lotus leaf, tea, infusion, hypertension, and blood pressure; NCT04651023 plus animal and in-vitro studies were excluded.
Why this is classified as ?
No evidence axes are scored because no eligible controlled human trial matched lotus-leaf tea, hypertension, and systolic blood pressure; the grade remains ?.
Counterpoint. Failure to identify evidence is neither proof of zero effect nor evidence of safety; the testable question remains unverified.
Rejudgment record. Independent Codex cross-check — One exact plant part, formulation, population, claim, endpoint, and comparator
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Fat reducing effects of Nelumbo nucifera leaf extract in overweight patients | Design and eligibility were independently checked. | 60 | Funding, product supply, employee authorship, and conflicts were assessed separately. | The endpoint was checked against the page claim. | No missing effect estimate or confidence interval was invented. | Eligibility reflects the exact plant part, formulation, population, endpoint, and comparator. |
| Seasonal Effects on Phenolic Contents and In Vitro Health-Promoting Bioactivities of Sacred Lotus | Design and eligibility were independently checked. | Funding, product supply, employee authorship, and conflicts were assessed separately. | The endpoint was checked against the page claim. | No missing effect estimate or confidence interval was invented. | Eligibility reflects the exact plant part, formulation, population, endpoint, and comparator. |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-09-08).
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Lotus Leaf Tea for Systolic Blood Pressure in Hypertension—No Direct Eligible Controlled Human Trial Was Identified — Evidence Grade ?. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/lotus-leaf-tea-hypertension-systolic-blood-pressure/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.